JP2013542930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542930A5 JP2013542930A5 JP2013531721A JP2013531721A JP2013542930A5 JP 2013542930 A5 JP2013542930 A5 JP 2013542930A5 JP 2013531721 A JP2013531721 A JP 2013531721A JP 2013531721 A JP2013531721 A JP 2013531721A JP 2013542930 A5 JP2013542930 A5 JP 2013542930A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- topical pharmaceutical
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 11
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims 5
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 5
- 206010000496 acne Diseases 0.000 claims 5
- 229960003679 brimonidine Drugs 0.000 claims 5
- 229960001528 oxymetazoline Drugs 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 208000010201 Exanthema Diseases 0.000 claims 3
- 206010043189 Telangiectasia Diseases 0.000 claims 3
- 201000005884 exanthem Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010037844 rash Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000009056 telangiectasis Diseases 0.000 claims 3
- 208000019872 Drug Eruptions Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 1
- 241001608562 Chalazion Species 0.000 claims 1
- 206010013786 Dry skin Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000009675 Perioral Dermatitis Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 241000220317 Rosa Species 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000009443 Vascular Malformations Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229960001724 brimonidine tartrate Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000037336 dry skin Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000008588 molluscum contagiosum Diseases 0.000 claims 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 claims 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical group Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 206010055031 vascular neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38726810P | 2010-09-28 | 2010-09-28 | |
| US61/387,268 | 2010-09-28 | ||
| US13/232,139 | 2011-09-14 | ||
| US13/232,139 US20120076738A1 (en) | 2010-09-28 | 2011-09-14 | Combination treatment for dermatological conditions |
| PCT/US2011/053455 WO2012050831A2 (en) | 2010-09-28 | 2011-09-27 | Combination treatment for dermatological conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013542930A JP2013542930A (ja) | 2013-11-28 |
| JP2013542930A5 true JP2013542930A5 (enExample) | 2014-09-18 |
Family
ID=45870879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013531721A Pending JP2013542930A (ja) | 2010-09-28 | 2011-09-27 | 皮膚科疾患の併用による治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20120076738A1 (enExample) |
| EP (1) | EP2621498A4 (enExample) |
| JP (1) | JP2013542930A (enExample) |
| KR (1) | KR20140056129A (enExample) |
| CN (1) | CN103354744A (enExample) |
| AU (1) | AU2011314151A1 (enExample) |
| CA (1) | CA2821993A1 (enExample) |
| MX (1) | MX2013003639A (enExample) |
| RU (1) | RU2013113188A (enExample) |
| WO (1) | WO2012050831A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130079312A1 (en) * | 2011-09-28 | 2013-03-28 | Elorac, Ltd. | Method of Treating Hair Loss Due to Systemic Chemotherapy |
| CA2911472A1 (en) * | 2013-05-06 | 2014-11-13 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| US20150258011A1 (en) * | 2014-03-15 | 2015-09-17 | Marty Richard Hunter | Treatment of keratinized tissues |
| MX2017010544A (es) * | 2015-02-24 | 2018-06-18 | Univ Illinois | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. |
| US9937117B2 (en) | 2015-07-09 | 2018-04-10 | Galderma S.A. | Method of reducing hair loss associated with chemotherapy |
| RU2605687C1 (ru) * | 2015-09-21 | 2016-12-27 | Ирина Николаевна Усманова | Способ лечения рецидивирующего афтозного стоматита |
| WO2018212846A1 (en) | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| EP3784260A4 (en) * | 2018-04-18 | 2022-03-09 | Forte Subsidiary, Inc. | Compositions for the treatment of skin conditions |
| MX2021001645A (es) * | 2018-08-29 | 2021-05-12 | Cellix Bio Private Ltd | Metodos y composiciones oftalmicas para el tratamiento de trastornos del ojo y enfermedades de la piel. |
| WO2020065085A1 (fr) * | 2018-09-28 | 2020-04-02 | Galderma Research & Development | Composition pharmaceutique comprenant de la brimonidine, et ses utilisations |
| JP2022516796A (ja) * | 2019-01-12 | 2022-03-02 | セリックス バイオ プライヴェート リミテッド | 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用 |
| EP3962478A1 (en) | 2019-05-01 | 2022-03-09 | Clexio Biosciences Ltd. | Methods of treating pruritus |
| US20220211672A1 (en) * | 2019-05-01 | 2022-07-07 | Clexio Biosciences Ltd. | Methods of treating pruritus |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| PT1761266E (pt) * | 2004-05-25 | 2013-06-04 | Galderma Pharma Sa | Compostos, formulações, e métodos para tratamento ou prevenção de distúrbios inflamatórios da pele |
| PL2182960T3 (pl) * | 2007-07-27 | 2014-08-29 | Galderma Laboratories Inc | Związki, preparaty i sposoby zmniejszania zmarszczek, zwiotczenia i pofałdowania skóry |
| US8114898B2 (en) * | 2007-11-16 | 2012-02-14 | Allergan, Inc. | Compositions and methods for treating purpura |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| CA2810746A1 (en) * | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
| US20120082625A1 (en) * | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
| EP2768502A2 (en) * | 2011-10-19 | 2014-08-27 | Galderma S.A. | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
-
2011
- 2011-09-14 US US13/232,139 patent/US20120076738A1/en not_active Abandoned
- 2011-09-27 AU AU2011314151A patent/AU2011314151A1/en not_active Abandoned
- 2011-09-27 JP JP2013531721A patent/JP2013542930A/ja active Pending
- 2011-09-27 CA CA2821993A patent/CA2821993A1/en not_active Abandoned
- 2011-09-27 EP EP11833012.5A patent/EP2621498A4/en not_active Withdrawn
- 2011-09-27 KR KR1020137010903A patent/KR20140056129A/ko not_active Ceased
- 2011-09-27 RU RU2013113188/15A patent/RU2013113188A/ru not_active Application Discontinuation
- 2011-09-27 WO PCT/US2011/053455 patent/WO2012050831A2/en not_active Ceased
- 2011-09-27 MX MX2013003639A patent/MX2013003639A/es unknown
- 2011-09-27 CN CN2011800470603A patent/CN103354744A/zh active Pending
-
2013
- 2013-12-10 US US14/101,464 patent/US20140094470A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/797,544 patent/US20150313895A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542930A5 (enExample) | ||
| RU2013113188A (ru) | Комбинированное лечение дерматологических состояний | |
| JP2013538853A5 (enExample) | ||
| JP2017537936A5 (enExample) | ||
| JP2013511534A5 (enExample) | ||
| BR112014009927A2 (pt) | "derivado de azol, composição farmacêutica que o compreende e uso do mesmo" | |
| JP2014505733A5 (enExample) | ||
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| JP2012036176A5 (enExample) | ||
| CO6640250A2 (es) | Formulación tópica que comprende (r)-3-ciclopentil-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo o una sal farmaceúticamente aceptable del mismo y una emulsión de aceite en agua | |
| JP2013522184A5 (enExample) | ||
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| Nuzzi et al. | Potent α-amino-β-lactam carbamic acid ester as NAAA inhibitors. Synthesis and structure–activity relationship (SAR) studies | |
| WO2012163928A3 (en) | Topical wash composition for use in acne patients | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| JP2014511393A5 (enExample) | ||
| WO2014140861A3 (en) | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | |
| BR112015023669A2 (pt) | novos derivados de ciclosporina e suas utilizações | |
| JP2018522875A5 (enExample) | ||
| JP2020525460A5 (enExample) | ||
| WO2013022243A3 (ko) | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
| SA519410993B1 (ar) | النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية | |
| MX2014014818A (es) | Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel. | |
| EA201590546A1 (ru) | Способы лечения заболеваний, связанных с волосами | |
| BR112015027436A8 (pt) | composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos |